CO2019013940A2 - Métodos para reducir o prevenir episodios cardiovasculares en pacientes con diabetes mellitus tipo ii - Google Patents
Métodos para reducir o prevenir episodios cardiovasculares en pacientes con diabetes mellitus tipo iiInfo
- Publication number
- CO2019013940A2 CO2019013940A2 CONC2019/0013940A CO2019013940A CO2019013940A2 CO 2019013940 A2 CO2019013940 A2 CO 2019013940A2 CO 2019013940 A CO2019013940 A CO 2019013940A CO 2019013940 A2 CO2019013940 A2 CO 2019013940A2
- Authority
- CO
- Colombia
- Prior art keywords
- methods
- patients
- reduce
- type
- diabetes mellitus
- Prior art date
Links
- 230000007211 cardiovascular event Effects 0.000 title 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 229960001713 canagliflozin Drugs 0.000 abstract 1
- VHOFTEAWFCUTOS-TUGBYPPCSA-N canagliflozin hydrate Chemical compound O.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1 VHOFTEAWFCUTOS-TUGBYPPCSA-N 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762518547P | 2017-06-12 | 2017-06-12 | |
| PCT/IB2018/054208 WO2018229630A1 (en) | 2017-06-12 | 2018-06-11 | Method for reducing or preventing cardiovascular events in patients with type ii diabetes mellitus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2019013940A2 true CO2019013940A2 (es) | 2020-01-17 |
Family
ID=62916717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2019/0013940A CO2019013940A2 (es) | 2017-06-12 | 2019-12-11 | Métodos para reducir o prevenir episodios cardiovasculares en pacientes con diabetes mellitus tipo ii |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20180353470A1 (enExample) |
| EP (1) | EP3638250A1 (enExample) |
| JP (2) | JP2020523408A (enExample) |
| KR (1) | KR20200014406A (enExample) |
| CN (1) | CN110740735A (enExample) |
| AU (1) | AU2018283781B2 (enExample) |
| BR (1) | BR112019026120A2 (enExample) |
| CA (1) | CA3066874A1 (enExample) |
| CO (1) | CO2019013940A2 (enExample) |
| EA (1) | EA202090028A1 (enExample) |
| IL (1) | IL271100A (enExample) |
| MX (1) | MX2019014988A (enExample) |
| TW (1) | TWI835735B (enExample) |
| UA (1) | UA127987C2 (enExample) |
| WO (1) | WO2018229630A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI827184B (zh) * | 2021-08-03 | 2023-12-21 | 國立政治大學 | 第2型糖尿病併發症的風險評估系統與方法 |
| CN117085009B (zh) * | 2023-10-20 | 2024-01-30 | 首都医科大学附属北京天坛医院 | 卡格列净对急性缺血性卒中的治疗作用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104109155A (zh) | 2003-08-01 | 2014-10-22 | 田边三菱制药株式会社 | 新颖化合物 |
| UY30730A1 (es) | 2006-12-04 | 2008-07-03 | Mitsubishi Tanabe Pharma Corp | Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno |
| ES2455124T5 (es) * | 2010-05-05 | 2018-05-08 | Zora Biosciences Oy | Biomarcadores lipidómicos para la aterosclerosis y afección cardíaca |
| JP5596799B2 (ja) * | 2010-05-11 | 2014-09-24 | 田辺三菱製薬株式会社 | カナグリフロジン含有錠剤 |
| US20160000816A1 (en) * | 2013-04-05 | 2016-01-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CA2812016A1 (en) * | 2013-04-05 | 2014-10-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CN105939728A (zh) * | 2014-01-31 | 2016-09-14 | 詹森药业有限公司 | 用于治疗和预防肾病和脂肪肝病的方法 |
| US20170071970A1 (en) * | 2015-09-15 | 2017-03-16 | Janssen Pharmaceutica Nv | Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders |
-
2018
- 2018-06-08 TW TW107119774A patent/TWI835735B/zh not_active IP Right Cessation
- 2018-06-11 JP JP2020517619A patent/JP2020523408A/ja active Pending
- 2018-06-11 BR BR112019026120-6A patent/BR112019026120A2/pt not_active Application Discontinuation
- 2018-06-11 EA EA202090028A patent/EA202090028A1/ru unknown
- 2018-06-11 CA CA3066874A patent/CA3066874A1/en active Pending
- 2018-06-11 US US16/004,607 patent/US20180353470A1/en not_active Abandoned
- 2018-06-11 MX MX2019014988A patent/MX2019014988A/es unknown
- 2018-06-11 UA UAA202000168A patent/UA127987C2/uk unknown
- 2018-06-11 KR KR1020207000103A patent/KR20200014406A/ko not_active Ceased
- 2018-06-11 WO PCT/IB2018/054208 patent/WO2018229630A1/en not_active Ceased
- 2018-06-11 EP EP18740894.3A patent/EP3638250A1/en not_active Withdrawn
- 2018-06-11 AU AU2018283781A patent/AU2018283781B2/en not_active Ceased
- 2018-06-11 CN CN201880039211.2A patent/CN110740735A/zh active Pending
-
2019
- 2019-12-02 IL IL271100A patent/IL271100A/en unknown
- 2019-12-11 CO CONC2019/0013940A patent/CO2019013940A2/es unknown
-
2020
- 2020-09-15 US US17/021,370 patent/US20210000792A1/en not_active Abandoned
-
2023
- 2023-05-10 JP JP2023077544A patent/JP2023113644A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| TWI835735B (zh) | 2024-03-21 |
| US20210000792A1 (en) | 2021-01-07 |
| EA202090028A1 (ru) | 2020-04-03 |
| AU2018283781B2 (en) | 2023-09-28 |
| CN110740735A (zh) | 2020-01-31 |
| US20180353470A1 (en) | 2018-12-13 |
| KR20200014406A (ko) | 2020-02-10 |
| JP2023113644A (ja) | 2023-08-16 |
| MX2019014988A (es) | 2020-08-06 |
| AU2018283781A1 (en) | 2019-12-19 |
| JP2020523408A (ja) | 2020-08-06 |
| BR112019026120A2 (pt) | 2020-07-07 |
| UA127987C2 (uk) | 2024-03-06 |
| WO2018229630A1 (en) | 2018-12-20 |
| TW201904584A (zh) | 2019-02-01 |
| CA3066874A1 (en) | 2018-12-20 |
| IL271100A (en) | 2020-01-30 |
| EP3638250A1 (en) | 2020-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP19021223A (es) | Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo | |
| CL2018002532A1 (es) | Composición farmacéutica que comprende empagliflozina y sus usos | |
| MX381599B (es) | Empagliflozina para usarse en el tratamiento de micro y macroalbuminuria | |
| CL2021001685A1 (es) | Anticuerpos anti-il-36r para el tratamiento de pustulosis palmoplantar | |
| CR20150337A (es) | Derivados de pirimidinona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral | |
| CL2019001214A1 (es) | Composición farmacéutica, métodos para tratamiento y sus usos. | |
| MX2015013948A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
| AR098738A1 (es) | Análogos del péptido exendina-4 no acilados | |
| MX2018015089A (es) | Combinacion de linagliptina y metformina. | |
| CO2017004932A2 (es) | Métodos para seleccionar una línea de células t y donador de la misma para terapia celular adoptiva | |
| ECSP16057765A (es) | Composiciones y métodos para reducir eventos adversos cardiovasculares graves | |
| MX2016016800A (es) | Metodos para el tratamiento del sobrepeso o la obesidad. | |
| UY35276A (es) | Nuevos compuestos que inhiben la actividad de Lp-PLA2 | |
| MX2017009294A (es) | Tratamiento de pacientes pediatricos con diabetes mellitus de tipo 2 con lixisenatida. | |
| CO2019004131A2 (es) | Glicinato de metformina, composiciones farmacéuticas que comprenden la misma, y métodos de uso de la misma | |
| MX2017001631A (es) | Una combinacion de vitamina d y zinc y su uso. | |
| UA117933C2 (uk) | Поліпептид, здатний зв'язувати с5-компонент комплементу людини | |
| BR112017016497A2 (pt) | composições e métodos para metabolismo muscular melhorado | |
| EA201992562A1 (ru) | Пептиды для лечения сахарного диабета | |
| CL2019000471A1 (es) | Formas sólidas de un compuesto de dihidroxi ciclopentilo disustituido con alfa, omega y métodos para su preparación y uso. (divisional solicitud 201601448) | |
| CR20170470A (es) | Tratamiento de pacientes con diabetes mellitus tipo 2 | |
| MX2016012127A (es) | Ostreolisina, variante de la misma funcionalmente relacionada, extracto que comprende ostreolisina y usos de los mismos. | |
| MX2018002298A (es) | Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos. | |
| MX2019014988A (es) | Uso de canagliflozina para reducir o prevenir episodios cardiovasculares en pacientes con diabetes mellitus tipo ii. | |
| MX2017015566A (es) | Tratamiento de enfermedades mitocondriales. |